

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bruno Michael Anthony</u> (Last) (First) (Middle) 228 STRAWBRIDGE DRIVE SUITE 100 (Street) MOORESTOWN NJ 08057 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2023	3. Issuer Name and Ticker or Trading Symbol <u>Tabula Rasa HealthCare, Inc. [TRHC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CHIEF ACCOUNTING OFFICER	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22,955 ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(5)	02/14/2029	Common Stock	1,250	55.13	D	
Employee Stock Option (right to buy)	(6)	02/14/2029	Common Stock	2,500	55.13	D	
Employee Stock Option (right to buy)	(7)	03/05/2029	Common Stock	723	54.76	D	
Employee Stock Option (right to buy)	(8)	03/05/2029	Common Stock	527	54.76	D	

Explanation of Responses:

- Amount includes a restricted stock award of 205 shares of the Company's common stock received by Mr. Bruno on February 24, 2020. Such common stock vested one-fourth on January 18, 2021 and has continued to vest in equal one-fourth installments annually thereafter.
- Amount includes a restricted stock award of 750 shares of the Company's common stock received by Mr. Bruno on January 28, 2021. Such common stock vested one-fourth on January 12, 2022 and has continued to vest in equal one-fourth installments annually thereafter.
- Amount includes a restricted stock award of 1,230 shares of the Company's common stock received by Mr. Bruno on October 15, 2021. Such common stock vested one-fourth on January 1, 2023 and has continued to vest in equal one-fourth installments annually thereafter.
- Amount includes a grant of 12,960 restricted stock units received by Mr. Bruno on May 1, 2023. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Such common stock will vest one-fourth on January 1, 2024, and will continue to vest in equal one-fourth installments annually thereafter.
- The Stock Option vested one-fourth on January 1, 2020 and vested in equal 1/36th installments each month thereafter.
- The Stock Option vested one-fourth on February 14, 2020 and vested in equal 1/36th installments each month thereafter.
- The Stock Option vested one-fourth on January 1, 2020 and vested in equal 1/36th installments each month thereafter.
- The Stock Option vested one-fourth on January 1, 2020 and vested in equal 1/36th installments each month thereafter.

/s/ Brian W. Adams, by
Power of Attorney

08/10/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS**

Know all by these presents, that the undersigned hereby constitutes and appoints each of Brian W. Adams, President and Chief Executive Officer of Tabula Rasa HealthCare, Inc. (the “**Company**”), and Richard W. Rew II, Chief Legal Officer and Corporate Secretary of the Company, or either of them acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or beneficial owner of more than 10% of the outstanding equity securities of the Company, Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), and the rules thereunder;
2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “**SEC**”) and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and
3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 4th day of August, 2023.

Signed and acknowledged:

/s/ Michael Bruno

Name: Michael Bruno

[Signature Page to Limited Power of Attorney]